Introduction {#Sec1}
============

Low-back pain is the fifth most common reason for all physician visits in the USA \[[@CR1], [@CR2]\]. Many patients have self-limited episodes of acute low-back pain and do not seek medical care \[[@CR3]\]. Among those who do seek medical care, pain, disability, and return to work typically improve rapidly in the first month \[[@CR4]\]. However, up to one-third of patients report persistent back pain of at least moderate intensity 1 year after an acute episode \[[@CR5], [@CR6]\].

Successful treatment of pain depends on identification of the involved mechanism and use of appropriate therapeutic approaches.

Woolf et al. \[[@CR7]\] proposed that pain symptoms and syndromes should be classified into two broad mechanism-based pain categories: tissue-injury pain (nociceptive) or nervous-system-injury pain (neuropathic). Chronic low-back pain (LBP) has been shown to be the result of neuropathic as well as nociceptive pain mechanisms \[[@CR8]--[@CR11]\]. Based on this evidence, it has been suggested that antidepressants and/or anticonvulsants in combination with either opioids, traditional nonsteroidal anti-inflammatory drugs or muscle relaxants could be useful in the treatment of this condition \[[@CR11]--[@CR13]\].

Even if there is increasing knowledge that different mechanisms of pain require appropriate treatments and often polypharmacotherapy, and although drug combination is frequently empirically adopted in clinical practice, prospective studies concerning the relative efficacy and safety of polypharmacotherapy compared with monotherapy are still relatively few \[[@CR14]--[@CR20]\].

Among the most commonly used agents to control neuropathic pain is pregabalin, which has been validated in different clinical settings \[[@CR14], [@CR21]--[@CR23]\], while celecoxib is a selective COX-2 inhibitor that has been proved to be effective in the treatment of different pain models that are considered predominantly of nociceptive origin \[[@CR24]--[@CR26]\].

Aim of this prospective, single-blind, randomized study was to compare the safety and efficacy of the association of celecoxib and pregabalin with monotherapy of each for treatment of chronic low-back pain in a mixed population of patients affected by chronic low-back pain and then to interpret the results by pooling the same patients according to Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale \[[@CR27], [@CR28]\].

Methods {#Sec2}
=======

In this 12-week, double-blind, prospective study, performed at our institution from 2006 to 2008, we compared the efficacy and tolerability of the combination of a selective COX-2 inhibitor, anti-inflammatory drug, celecoxib and an antineuropathic drug, pregabalin, versus either celecoxib or pregabalin plus placebo, in the treatment of chronic LBP due to disc prolapse, lumbar spondylosis, and/or spinal stenosis.

The study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki as revised in 2000 and approved by the Institutional Review Board. Informed consent was obtained from each subject at recruitment.

Patient population {#Sec3}
------------------

Of the originally enrolled 42 patients, 36 completed the study, 16 men and 20 women (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and anamnestic patient data (*n* = 36)Patient characteristicsTotal numberSex Male16 Female20Race White33 Black1 Asian2Mean age (years)53 ± 16Mean weight (kg)71 ± 14Smoking habits Smoker13 Ex-smoker5 Nonsmoker18Previous use of medications30Causes of LBP (may be associated) Disc prolapse17 Lumbar spondylosis14 Spinal canal stenosis7

Inclusion criteria were the following:Chronic low-back pain (symptoms duration: \>6 months, mean: 13 ± 6 months) due to disc prolapse, lumbar spondylosis, and/or spinal stenosis;Minimum VAS at recruitment: \>40 mmAge: \>18 years, \<75 years;Informed consent.

Exclusion criteria:Previous back surgery;Diabetes;Neurological disease;Cardio-renal disease;History of gastric ulcers or intestinal bleeding;Known allergy to the drugs under study;Alcohol or drug abuse.

Once the patient was found eligible to participate in the study, informed consent was obtained.

Assessment {#Sec4}
----------

Primary outcomes was mean pain reduction following different treatments regimes. Secondary outcomes were adverse effects due to the treatments under study.

Before starting treatment, demographic and anthropometric data, as well as a medical history, were collected. All patients were assessed by visual analogue scale (100 mm), LANSS, and radiographically.

Visual analogue scale was evaluated at patient recruitment and before and after any 4-week treatment period by an investigator blinded to the administered pharmacological treatment.

The LANSS pain scale consisted of a two-sided A4 sheet and was designed to be used in interview format during a single session. The interview, performed at recruitment, consisted of the clinician reading the questionnaire and asking the patient whether the description matched their pain characteristics in the preceding week. This session was followed by a bedside examination for any sensory dysfunction and specifically for allodynia and for altered pinprick threshold (PPT). Allodynia was judged to be present when pain was elicited by the gentle stroke of a piece of cotton over the painful area in comparison with a nonpainful area. PPT was determined by comparing the response to a 23-gauge needle mounted inside a 2-mL syringe barrel placed onto the skin in nonpainful and then painful areas several times. PPT was defined as a sharp sensation in relation to gentle needle placement in a painful area. According to the LANSS pain scale, the frequency of each item of the five pain symptoms, as well as the two sensory examination items, was calculated for every patient. Dysesthesia and autonomic dysfunction were given a score of 5 each, if present. Evoked pain was given a score of 3. Paroxysmal pain was given a score of 2. Thermal pain was given a score of 1. For testing sensory dysfunction, allodynia, if found, was given a score of 5, and altered PPT was given a score of 3. Accordingly, the total summed scores had a maximum of 24 points. Patients with a score less than 12 were considered unlikely to have neuropathic low-back pain, whereas patients with a score of 12 or more were considered to have a neuropathic element that contributed to their low-back pain. Neither psychological status nor social class of patients was included in the study.

Treatment regime {#Sec5}
----------------

After a discontinuation period of at least 7 days from any previous analgesic treatment and between treatments, each patient received the following three consecutive treatments regimes:Celecoxib (approximately 3--6 mg/kg/die) + placebo;Pregabalin (approximately 1 mg/kg/die the first week and then 2--4 mg/kg/die) + placebo;Celecoxib (approximately 3--6 mg/kg/die) plus pregabalin (approximately 1 mg/kg/die the first week and then 2--4 mg/kg/die).

Each treatment lasted 4 weeks, with 1-week discontinuation between treatments (Table [2](#Tab2){ref-type="table"}). The sequence of treatments in each patient was randomly assigned as follows, based on consecutive recruitment order: first patient received celecoxib + placebo, pregabalin + placebo, celecoxib + pregabalin; second patient received pregabalin + placebo, celecoxib + pregabalin, celecoxib + placebo; third patient received celecoxib + pregabalin, celecoxib + placebo, pregabalin + placebo; and so on.Table 2Experimental setupWeekActionCohort 1 (*N* = 12)Cohort 2 (*N* = 12)Cohort 3 (*N* = 12)0Patient's recruitment/assessment/randomization. Any treatment discontinuation1VAS assessmentStarts treatment CStarts treatment C + PStarts treatment P5Treatment discontinuation and VAS assessment6VAS assessmentStarts treatment PStarts treatment CStarts treatment C + P10Treatment discontinuation and VAS assessment11VAS assessmentStarts treatment P + CStarts treatment PStarts treatment C15Treatment discontinuation and VAS assessment*C* celecoxib + placebo, *P* pregabalin + placebo, *C* + *P* celecoxib + pregabalin

Concomitant use of antidepressants and/or anticonvulsants, opioids, nonsteroidal anti-inflammatory drugs or muscle relaxants was not permitted during the 12-week study.

Statistical analysis {#Sec6}
--------------------

Descriptive statistics were determined by calculation of the mean and standard deviation (±SD). Statistical analysis was performed with Student's *t* test.

Stratification on the basis of LANSS pain scale score (with a score of 12 or more as the cutoff point) was done for intergroup comparison.

Results throughout the text, tables, and figures are presented as mean ± SD unless otherwise specified, and statistical significance was defined as *P* \< 0.05. Sample size was chosen according to a minimum expected difference in pain control of different treatment regimes of 10%.

Results {#Sec7}
=======

Of the 42 patients initially recruited for the study, 6 decided to discontinue the treatment or did not present themselves at the programmed controls and were then excluded from data analysis. Among these six patients, four (one taking celecoxib alone, one taking pregabalin alone, two taking pregabalin + celecoxib) refused to continue the treatment within the first 2 weeks due to reported epigastralgia and/or nausea, one patient was lost to follow-up after 22 days due to logistical problems (work travelling outside Italy), and one due to intercurrent trauma (car accident). All presented data will be referred to the remaining 36 patients who completed the study and were available at follow-up.

Of 36 patients, 20 had LANSS pain scale score \<12, while the remaining 16/36 were rated \>12.

Table [3](#Tab3){ref-type="table"} summarizes mean ± standard deviation of recorded VAS immediately prior to the beginning of each treatment regime and after the 4-week treatment period. According to the statistical analysis of data, also provided in the same table, celecoxib + placebo and pregabalin + placebo did produce a statistically significant reduction of reported pain, in patients with LANSS score \<12 (*P* = 0.01) and in patients with LANSS score \>12 (*P* = 0.03), but not in the general population of patients studied. On the contrary, the association pregabalin + celecoxib resulted in a statistically significant reduction of self-reported pain when considering either all the recruited patients or the subpopulations divided according to LANSS score. The drug combination also proved more effective that pregabalin alone and more effective than celecoxib alone, except for patients with LANSS score \<12.Table 3Self-reported VAS before and after each 4-week treatment regimePretreatmentEnd of 4-week treatment*P* value (end of treatment versus pretreatment)*P* value (drug combination versus celecoxib + placebo)*P* value (drug combination versus pregabalin + placebo)MeanSDMeanSDCelecoxib + placebo (all patients, *N* = 36)45.113.139.512.20.06Celecoxib + placebo (LANSS \<12, *N* = 20)43.812.932.515.5**0.01**Celecoxib + placebo (LANSS \>12, *N* = 16)46.813.645.714.30.8Pregabalin + placebo (*N* = 36)48.114.243.113.50.12Pregabalin + placebo (LANSS \<12, *N* = 20)49.413.250.713.80.76Pregabalin + placebo (LANSS \>12, *N* = 16)47.215.036.312.7**0.03**Celecoxib + pregabalin (all patients, *N* = 36)46.313.828.615.1**0.00010.0010.0001**Celecoxib + pregabalin (LANSS \<12, *N* = 20)45.114.232.913.9**0.009**0.9**0.0002**Celecoxib + pregabalin (LANSS \>12, *N* = 16)47.915.223.114.6**0.00010.00010.01**Bold values indicate *P* \< 0.05

Figure [1](#Fig1){ref-type="fig"} summarizes the percentage pain reduction following the different treatment regimes. When all patients were considered, celecoxib alone provided 12.4% pain reduction, pregabalin alone 10.4%, and their combination 38.2%. The largest pain reduction (51.8%) was observed with the association pregabalin + celecoxib in patients with LANSS score \>12.Fig. 1Percentage pain reduction at the end of each 4-week treatment regime: mean VAS at the end of treatment/mean pretreatment VAS

Drugs consumption {#Sec8}
-----------------

The dosage of each drug was established at the beginning of each treatment period on the basis of each patient weight, but it could be modified during the treatment course by the physician, according to the pain and side-effects reported by the patients. Overall drug consumption by any single patient was tracked. During celecoxib + placebo treatment, mean celecoxib consumption was 4.12 ± 0.93 mg/kg/die; during pregabalin + placebo treatment it was 2.12 ± 0.69 mg/kg/die; and during celecoxib + pregabalin treatment it was 3.75 ± 0.86 and 1.78 ± 0.64 mg/kg/die, respectively. The difference of pregabalin and celecoxib consumption, when used in association, compared with monotherapies, was statistically significant for pregabalin (*P* \< 0.05) but not for celecoxib (*P* = 0.09).

Adverse effects {#Sec9}
---------------

Of the initially recruited 42, 4 (9%) discontinued treatment early due to side-effects and were not considered for further analysis of results. Of the remaining 36 patients, side-effects were recorded in 16 (44.4%) patients but did not require treatment discontinuation. Four had epigastralgia and nausea during celecoxib + placebo treatment, five reported nausea or dizziness after pregabalin + placebo, and seven experienced similar symptoms during treatment with celecoxib plus pregabalin.

Discussion {#Sec10}
==========

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently prescribed medications worldwide and are widely used for patients with low-back pain. Selective COX-2 inhibitors are currently available and used for patients with low-back pain. A recently published systematic Cochrane review of randomized controlled trials has shown the efficacy of NSAIDs and COX-2 inhibitors in the treatment of nonspecific low-back pain. In 65 trials (total number of patients = 11,237) statistically significant effects were found in favor of NSAIDs compared with placebo, but at the cost of statistically significant more side-effects. COX-2 NSAIDs had statistically significantly fewer side-effects than traditional NSAIDs \[[@CR29]\].

Pregabalin is a ligand for the alpha-2-delta subunit of voltage-gated calcium channels with anticonvulsant, analgesic, and anxiolytic properties. It has predictable absorption across the gastrointestinal tract, is neither metabolized nor protein bound, and has minimal drug--drug interactions. Pregabalin has been widely studied for the treatment of neuropathic pain and was shown in prospective randomized clinical trials to be effective for postherpetic neuralgia and painful diabetic peripheral neuropathy, with approximately 50% responder rates. Pregabalin is also usually well tolerated in most patients, with infrequent severe adverse effects \[[@CR30]\]. It has also been proved to be effective in other painful conditions, such as fibromyalgia \[[@CR31], [@CR32]\].

Pregabalin and its older companion, gabapentin, have already been successfully used in combination with other analgesic drugs to improve pain control. Gilron et al. \[[@CR16]\] first reported on the efficacy and safety of a combination of gabapentin and morphine compared with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia. In 41 patients who completed the trial, gabapentin-morphine combination showed significantly better pain control (*P* \< 0.05) versus placebo, gabapentin, and morphine. The group from the Ospedale Tor Vergata in Rome more recently published the Multicenter Italian Study, which compared the efficacy, safety, and quality of life of combination therapy with controlled-release (CR) oxycodone plus pregabalin versus monotherapy in patients with neuropathic pain \[[@CR33]\]. This study showed in 409 patients that the combination of CR oxycodone plus pregabalin and CR oxycodone monotherapy were both more effective for alleviating neuropathic pain than was pregabalin monotherapy (reduction in an 11-point numerical rating scale of 80%, 76%, and 46%, respectively; *P* = 0.003). Extremely significantly greater improvements from baseline in quality of life were reported with combination therapy than with monotherapy (*P* = 0.0009), and combination therapy also allowed dose reduction of both agents (22% for CR oxycodone and 51% for pregabalin) compared with dosages of the respective monotherapies.

Other studies compared the efficacy of pregabalin or gabapentin in combination with different analgesic agents for postoperative pain. Gilron et al. \[[@CR15]\] demonstrated, in a placebo-controlled randomized clinical trial on pain after abdominal hysterectomy, that perioperative administration of a combination of gabapentin and rofecoxib was significantly superior (*P* \< 0.05) over monotherapy, with similar adverse effects, except sedation which was more frequent with gabapentin alone. The association of gabapentin with celecoxib was found by Parsa and co-workers \[[@CR18]\] to be significantly superior (*P* \< 0.001) in reducing postoperative pain and opioid requirements than celecoxib alone in patients undergoing bilateral subpectoral breast augmentation.

Recently the association of pregabalin and of buprenorphine TDS and pregabalin in the treatment of low-back pain has been described \[[@CR19]\]. In 22 patients buprenorphine provided a meaningful pain reduction (VAS 82.75 ± 15 versus 138.25 ± 5, *P* \< 0.01), but the association of low doses of pregabalin allowed a further reduction of the VAS (*P* \< 0.01).

Michael Bennett in 2001 \[[@CR27]\] introduced the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale. The LANSS has subsequently been tested and validated in several settings, with sensitivity and specificity ranging from 82% to 91% and 80% to 94%, respectively, compared with clinical diagnosis \[[@CR34]\]. After Baron and Binder \[[@CR8]\] first introduced in 2004 the concept of mixed pain for sciatica, studies were published that confirmed the participation of nociceptive as well as neuropathic mechanisms of low-back pain. Kaki et al. \[[@CR11]\] applied the LANSS pain scale in a total of 1,169 patients from 117 centers; 639 patients (54.7%) had scores of 12 points or more, which suggested a neuropathic type of pain, and 530 patients (45.3%) had scores of less than 12, which suggested a nociceptive type of pain. These authors concluded that neuropathic pain is a major contributor to chronic low-back pain and that the LANSS pain scale is a useful tool to distinguish patients with neuropathic pain from those with nociceptive pain.

To our knowledge, this is the first report of the efficacy of both celecoxib and pregabalin for the treatment of chronic low-back pain. The rate of treatment discontinuation (4/42, 9%), falls well within that reported for both drugs under study \[[@CR14], [@CR21]--[@CR26]\]. We could also show that the relative efficacy of either monotherapy seems to correlate well with the outcome of the LANSS score and that combination of celecoxib and pregabalin proved to be superior to either single agent, with comparable side-effects and reduced mean consumption of any single drug (calculated as mean administered dosage per patient weight).
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